1. Home
  2. ADCT

as 05-28-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Founded: N/A Country:
Switzerland
Switzerland
Employees: N/A City: EPALINGES
Market Cap: 354.1M IPO Year: 2020
Target Price: $7.00 AVG Volume (30 days): 559.4K
Analyst Decision: Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.77 EPS Growth: N/A
52 Week Low/High: $0.36 - $6.04 Next Earning Date: 05-06-2024
Revenue: $68,619,000 Revenue Growth: -62.38%
Revenue Growth (this year): 13.94% Revenue Growth (next year): 18.73%

Stock Insider Trading Activity of ADC Therapeutics SA (ADCT)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
MALLIK AMEET ADCT Chief Executive Officer May 7 '24 Sell $4.48 29,731 $133,194.88 1,167,348 SEC Form 4

Share on Social Networks: